Bevacizumab in metastatic breast cancer: A meta-analysis of randomized controlled trials

Breast Cancer Research and Treatment

Volumn 122, Issue 1, 2010, Pages 1-7

  Valachis, A ^a,b   Polyzos, N P ^b,c   Patsopoulos, N A ^d   Georgoulias, V ^a   Mavroudis, D ^a   Mauri, D ^b,e  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Oncology and Obstetrics and Gynaecology   (Greece)

^c Technical University of Larisa   (Greece)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e General Hospital of Lamia   (Greece)

Author keywords

Advanced; Avastin; Bevacizumab; Breast cancer; Chemotherapy; Meta analysis; Metastatic

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; METHOTREXATE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; TAXOID;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; SURVIVAL; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 73449097493     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0727-0     Document Type: Review

References (20)

1. G Mariani 2005 New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy Ann Oncol 16 suppl 2 ii191 ii194 10.1093/annonc/mdi719 15958455 (Pubitemid 40908955)
2. N Weidner J Folkman F Pozza, et al. 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 1875 1887 10.1093/jnci/84.24.1875 1:STN:280: DyaK3s%2FpsFWhtA%3D%3D 1281237
3. B Uzzan P Nicolas M Cucherat GY Perret 2004 Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and metaanalysis Cancer Res 64 9 2941 2955 10.1158/0008-5472.CAN-03- 1957 1:CAS:528:DC%2BD2cXjs1ehsLw%3D 15126324 (Pubitemid 38581387)
4. SW McLeskey CA Tobias PR Vezza AC Filie FG Kern J Hanfelt 1998 Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor Am J Pathol 153 6 1993 2006 1:CAS:528:DyaK1cXotV2rs7s%3D 9846989
5. B Linderholm K Grankvist N Wilking M Johansson B Tavelin R Henriksson 2000 Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 7 1423 1431 1:CAS:528: DC%2BD3cXivVeisro%3D 10735889
6. LJ Scott 2007 Bevacizumab: in first-line treatment of metastatic breast cancer Drugs 67 12 1793 1799 10.2165/00003495-200767120-00009 1:CAS:528:DC%2BD2sXhtFGgtb%2FM 17683175 (Pubitemid 47263182)
7. K Miller D Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NA Davidson 2007 Paclitaxel plus bevacizumab versus paclitacel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
8. X Pivot S Verma C Thomssen JL Passos-Coelho L Latini E Ciruelos M Silva R von Moos H Chang DW Miles 2009 Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or metastatic breast cancer J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 abstr 1094
9. NJ Robert V Dieras J Glaspy A Brufsky I Bondarenko O Lipatov E Perez E Yardley X Zhou S Phan 2009 RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 abstr 1005
10. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 3 177 188 10.1016/0197-2456(86)90046-2 1:STN:280:DyaL2s7gsVamtA%3D%3D 3802833 (Pubitemid 17189972)
11. W Cochran 1954 The combination of estimates from different experiments Biometrics 10 101 129 10.2307/3001666
12. JPT Higgins SG Thompson 2002 Quantifying heterogeneity in a meta-analysis Stat Med 21 1539 1558 10.1002/sim.1186 12111919 (Pubitemid 34746062)
13. JPT Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analyses BMJ 327 557 560 10.1136/bmj.327.7414.557 12958120
14. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing V Langmuir HS Rugo 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 4 792 799 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D 15681523 (Pubitemid 46224178)
15. HJ Burstein D Spigel K Kindsvogel LM Parker CA Bunnell AH Partridge SE Come PD Ryan R Gelman EP Winer 2005 Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study Breast Cancer Res Treat 94 Suppl 1 S6
16. G Daniele R Marciano G Tortora 2008 The role of bevacizumab in breast cancer Eur J Cancer Suppl 6 26 29 10.1016/j.ejcsup.2008.06.006 1:CAS:528:DC%2BD1MXhtVGgt7s%3D
17. H Yoshiji SR Harris UP Thorgeirsson 1997 Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells Cancer Res 57 18 3924 3928 1:CAS:528:DyaK2sXmtFehs7o%3D 9307273
18. M Relf S LeJeune PA Scott, et al. 1997 Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 963 969 1:CAS:528:DyaK2sXhs1Khsrw%3D 9041202
19. LA Stewart MKB Parmar 1993 Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341 418 422 10.1016/0140-6736(93)93004-K 1:STN:280:DyaK3s7ls1GitA%3D%3D 8094183 (Pubitemid 23048157)
20. JP Ioannidis TA Trikalinos 2007 The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey CMAJ 176 8 1091 1096 17420491